Damora Therapeutics Schedule 13G/A reports 0.0% stake
Damora Therapeutics amended a Schedule 13G/A to disclose reporting by Jain Global LLC, Jain Holdings LLC, and Robert Jain concerning Common Stock (CUSIP 36322Q206).
Rhea-AI Filing Summary
Damora Therapeutics amended a Schedule 13G/A to disclose reporting by Jain Global LLC, Jain Holdings LLC, and Robert Jain concerning Common Stock (CUSIP 36322Q206). The filing states the Reporting Persons hold 0.0% of the class and reports $0.00001 par value per share; ownership rows on the cover show zeros for voting and dispositive powers.
The amendment is signed by an authorized signatory and notes a previously filed power of attorney; it is an ownership disclosure for holders of 5% or less.
Positive
- None.
Negative
- None.
Insights
Disclosure confirms passive/minimal holding by reporting entities.
The filing lists Jain Global LLC, Jain Holdings LLC, and Robert Jain as joint filers regarding Shares of Damora Therapeutics (CUSIP 36322Q206). The cover rows show 0.0% ownership and zero voting/dispositive power entries, indicating holdings at or below the 5% reporting threshold.
Cash‑flow treatment and specific share counts are not shown in the excerpt; subsequent amendments would show any material changes if reporting persons cross thresholds.
Amendment documents signature authority and procedural linkage to prior POA.
The amendment incorporates a previously filed power of attorney and identifies Noah Goldberg signing as authorized signatory and attorney‑in‑fact. This clarifies execution authority for the Schedule 13G/A filings.
Filing mechanics and the Ownership of 5 Percent or Less of a Class classification are explicit; materiality to shareholders is routine and procedural.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned regulatory
dispositive power regulatory
power of attorney legal
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Damora Therapeutics' Schedule 13G/A with symbol DMRA disclose?
Who are the Reporting Persons named in the DMRA Schedule 13G/A?
Does the Schedule 13G/A show any beneficial ownership percentage for DMRA?
Who signed the Schedule 13G/A amendment for DMRA and under what authority?
Does this filing indicate a change that requires further SEC disclosure for DMRA?
AI-generated analysis. How Rhea-AI works. Not financial advice.